Skip to main content
. 2013 Jun 14;27(7):573–582. doi: 10.1007/s40263-013-0074-x

Table 3.

Results of meta-analyses—difference versus placebo

graphic file with name 40263_2013_74_Tab3_HTML.jpg

Grey highlighting indicates a significant result

ITT intent to treat, LOCF last observation carried forward, MD mean difference, Mono monotherapy, OC observed cases, PBO placebo, SMD standardized mean difference, as reported in individual studies

* For both MD and SMD a positive value represents a favorable outcome for memantine

** Studies MEM-MD-01 and MEM-MD-02 were excluded due to the nonavailability of the adjusted differences between treatments in the corresponding publications

§Based on study MEM-MD-02 only (data taken from the Cochrane review for cognition and activities of daily living as data not reported in the PenTAG analysis)